- Home
- XBIT vs ZTEK Comparison
XBIT vs ZTEK Comparison
Compare XBIT & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBIT | ZTEK |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.2M | 78.2M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | XBIT | ZTEK |
|---|---|---|
| Price | $2.65 | $0.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 48.6K | 45.3K |
| Earning Date | 11-12-2025 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $657,134.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2225.73 |
| 52 Week Low | $2.09 | $0.62 |
| 52 Week High | $4.54 | $1.84 |
Technical Indicators
Market Signals| Indicator | XBIT | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | 58.82 | 59.64 |
| Support Level | $2.40 | $0.64 |
| Resistance Level | $2.55 | $0.75 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 81.58 | 76.77 |
Price Performance
Historical ComparisonAbout XBIT XBiotech Inc.
XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.